Univasc Related Published Studies
Well-designed clinical trials related to Univasc (Moexipril)
Moexipril shows a long duration of action related to an extended pharmacokinetic half-life and prolonged ACE inhibition. [2002.01]
Efficacy and tolerability of moexipril and nitrendipine in postmenopausal women with hypertension. MADAM study group. Moexipril as Antihypertensive Drug After Menopause. [1999.05]
Co-administration of an ACE-inhibitor (moexipril) and hormonal replacement therapy in postmenopausal women. [1999.05]
Comparison between moexipril and atenolol in obese postmenopausal women with hypertension. [1998.09.20]
Increased arterial distensibility in postmenopausal hypertensive women with and without hormone replacement therapy after acute administration of the ACE inhibitor moexipril. [1998.09]
Antihypertensive treatment in postmenopausal women: results from a prospective, randomized, double-blind, controlled study comparing an ACE inhibitor (moexipril) with a diuretic (hydrochlorothiazide). [1998.05]
Antihypertensive effectiveness of a very low fixed-dose combination of moexipril and hydrochlorothiazide. [1998.03]
Usefulness of moexipril and hydrochlorothiazide in moderately severe essential hypertension. [1997.04]
Antihypertensive treatment with moexipril plus HCTZ vs metoprolol plus HCTZ in patients with mild-to-moderate hypertension. [1997.02]
Moexipril versus captopril in patients with mild to moderate hypertension. [1996.12]
A comparison of the antihypertensive effectiveness of a combination of moexipril or sustained-release verapamil with low-dose hydrochlorothiazide. [1996.08]
Moexipril as add-on therapy to hydrochlorothiazide in moderate to severe hypertension. [1996.07]
Lack of a pharmacokinetic interaction between moexipril and hydrochlorothiazide. [1996]
Evaluation of the antihypertensive efficacy and tolerability of moexipril, a new ACE inhibitor, compared to hydrochlorothiazide in elderly patients. [1996]
Long-term safety and efficacy of moexipril alone and in combination with hydrochlorothiazide in elderly patients with hypertension. [1995.11]
Moexipril in the treatment of mild to moderate essential hypertension: comparison with sustained-release verapamil. [1995.08]
Antihypertensive effects of moexipril, a new ACE inhibitor, as add-on therapy to nifedipine in patients with essential hypertension. [1995.07]
Comparison of moexipril, a new ACE inhibitor, to verapamil-SR as add-on therapy to low dose hydrochlorothiazide in hypertensive patients. [1995.04]
Tricenter assessment of the efficacy of the ACE inhibitor, moexipril, by ambulatory blood pressure monitoring. [1995.03]
Long-term efficacy and safety of moexipril in the treatment of hypertension. [1994.12]
Comparison of the efficacy of three dose levels of moexipril versus placebo as add-on therapy to hydrochlorothiazide in patients with moderate hypertension. [1994.08]
Moexipril does not alter the pharmacokinetics or pharmacodynamics of warfarin. [1993]
Other research related to Univasc (Moexipril)
Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid. [2010.02]
Moexipril and left ventricular hypertrophy. [2007]
Subchronic exposure to high-dose ACE-inhibitor moexipril induces catalase activity in rat liver. [2005.12]
MORE--MOexipril and REgression of left ventricle hypertrophy in combination therapy A multicentric open label clinical trial. [2005.04.20]
Regression of left ventricular hypertrophy with moexipril, an angiotensin-converting enzyme inhibitor, in hypertensive patients. [2005.01]
Pharmacological and clinical profile of moexipril: a concise review. [2004.08]
The influence of relative humidity and temperature on stability of moexipril hydrochloride in solid phase. [2004.03]
Pharmacological profile and clinical use of moexipril. [2003.09]
Moexipril and quinapril inhibition of tissue angiotensin-converting enzyme activity in the rat: evidence for direct effects in heart, lung and kidney and stimulation of prostacyclin generation. [2003.01]
ACE Inhibition with moexipril: a review of potential effects beyond blood pressure control. [2003]
Enalapril and moexipril protect from free radical-induced neuronal damage in vitro and reduce ischemic brain injury in mice and rats. [1999.05.28]
Moexipril. A review of its use in the management of essential hypertension. [1998.06]
Impact of antihypertensive therapy on the skeleton: effects of moexipril and hydrochlorothiazide on osteopenia in spontaneously hypertensive ovariectomized rats. [1997.09]
Impact of antihypertensive therapy on postmenopausal osteoporosis: effects of the angiotensin converting enzyme inhibitor moexipril, 17beta-estradiol and their combination on the ovariectomy-induced cancellous bone loss in young rats. [1995.12]
A Study of the Efficacy and Safety of Moexipril in Mild to Moderate Hypertension. [1995.11]
The Antihypertensive Properties of the Angiotensin-Converting Enzyme Inhibitor Moexipril Given Alone or in Combination with a Low Dose of a Diuretic. [1995.08]
Other possibly related research studies
Using ACE inhibitors appropriately. [2002.08.01]
Angiotensin-converting enzyme inhibition in infarct-induced heart failure in rats: bradykinin versus angiotensin II. [1994.10]
Systemic hypertension in postmenopausal women: a clinical approach. [2002.12]
Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. [2002]
Pharmacologic, pharmacokinetic, and therapeutic differences among ACE inhibitors. [1998.05]
Trough/peak ratios of once daily angiotensin converting enzyme inhibitors and calcium antagonists. [1996.07]
Compliance, persistence, healthcare resource use, and treatment costs associated with aliskiren plus ARB versus ACE inhibitor plus ARB combination therapy: in US patients with hypertension. [2011]
|